PRESS RELEASE

from Viromed Medical AG (isin : DE000A3MQR65)

Viromed Medical AG signs distribution partnerships for ViroCAP® in six additional markets

EQS-News: Viromed Medical AG / Key word(s): Alliance
Viromed Medical AG signs distribution partnerships for ViroCAP® in six additional markets

10.08.2026 / 15:56 CET/CEST
The issuer is solely responsible for the content of this announcement.


CORPORATE NEWS

Viromed Medical AG signs distribution partnerships for ViroCAP® in six additional markets

Rellingen, 10 August 2026 – Viromed Medical AG (“Viromed”; ISIN: DE000A3MQR65), a medical technology company and pioneer in cold plasma technology, has entered into several new distribution partnerships for its ViroCAP® product. The agreements provide for distribution in Spain, Portugal, Greece, the Balkan region, Romania and Saudi Arabia, significantly expanding the company’s international presence. The agreements were concluded with six separate companies and each relate to an individual market. Minimum purchase quantities were agreed in each of the partnerships. On the basis of these contracts, Viromed expects additional sales of at least 3,000 devices per year.

ViroCAP® is a mobile medical device for the treatment of skin conditions using cold atmospheric plasma. It is aimed at hospitals, physicians in private practice and surgically active medical specialists.

Uwe Perbandt, Chief Executive Officer of Viromed Medical AG: “With these new distribution partners, we are opening up several attractive markets in Southern and South-Eastern Europe as well as in the Middle East. The strong interest shown by our distribution partners underlines the high demand for our cold plasma technology. The new distribution partnerships are another important step in the implementation of our dynamic growth phase. Partnerships for additional countries are in preparation and are expected to be signed within the next four to six weeks.”

With these new agreements, Viromed continues to expand its international distribution network. The company already has numerous distribution and marketing partnerships in place. These include, among others, the exclusive distribution agreement with the Korean company UMECO, covering ten Asian countries, as well as a distribution partnership with TriPart TITAN GmbH & Co. KG for the Turkish market.


About Viromed Medical AG

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.

www.viromed-medical-ag.de

Contact Viromed

E-Mail: kontakt@viromed-medical.de

Press contact

E-Mail: viromed@kirchhoff.de



10.08.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language:English
Company:Viromed Medical AG
Hauptstraße 105
25462 Rellingen
Germany
E-mail:kontakt@viromed-medical.de
Internet:https://www.viromed-medical-ag.de/
ISIN:DE000A40ZVN7
WKN:A40ZVN
Listed:Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX
LEI Code:894500XR05MYCVCCR171
EQS News ID:2380184

 
End of NewsEQS News Service

2380184  10.08.2026 CET/CEST

See all Viromed Medical AG news